Histone deacetylase inhibitors and genomic instability
Cancer Letters, ISSN: 0304-3835, Vol: 274, Issue: 2, Page: 169-176
2009
- 110Citations
- 70Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations110
- Citation Indexes109
- 109
- CrossRef101
- Patent Family Citations1
- Patent Families1
- Captures70
- Readers70
- 70
Article Description
Histone deacetylase inhibitors (HDACIs) are a promising new class of anticancer drugs. However, their mechanism of action has not been fully elucidated. Most studies have investigated the effect of HDACIs on the regulation of gene transcription. HDAC inhibition also leads to genomic instability by a variety of mechanisms. This phenomenon, which has been largely overlooked, may contribute to the cytotoxic effects of these drugs. Indeed, HDACIs sensitize DNA to exogenous genotoxic damage and induce the generation of reactive oxygen species. Moreover, HDACIs target mitosis resulting in chromosome segregation defects. Here, we review the effects of HDACI treatment on DNA damage and repair, and chromosome segregation control.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S030438350800459X; http://dx.doi.org/10.1016/j.canlet.2008.06.005; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=58149310725&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/18635312; https://linkinghub.elsevier.com/retrieve/pii/S030438350800459X; https://dx.doi.org/10.1016/j.canlet.2008.06.005
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know